Radiation and immunotherapy before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new way to treat triple-negative breast cancer before surgery by combining radiation therapy with an immunotherapy drug and chemotherapy. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with triple-negative breast cancer that has not spread to distant organs.
- Your cancer is at a stage where it can be treated with radiation therapy and surgery.
- Your tumor has a low level of a protein called PD-L1 (a marker that may affect treatment response).
- You are generally in good health, with adequate organ function (kidney, liver, blood counts).
- If you can become pregnant, you agree to use contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for breast cancer that combines a short course of focused radiation (SBRT) with an injection of the immunotherapy drug pembrolizumab directly into the tumor, followed by standard chemotherapy before surgery. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests a new drug combination given before surgery for triple-negative breast cancer. The drugs include an immunotherapy medication (AK112) and standard chemotherapy, and the goal is to see if it helps shrink the tumor and improve outcomes.
Hear when a new Breast Cancer Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.